{"id":583002,"date":"2026-05-22T00:00:00","date_gmt":"2026-05-22T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unnehe0003-2026-biopharma-immune-thrombocytopenic-purpura-unmet-need-unmet-need-immune-thrombocytopenic-purpura-us-eu\/"},"modified":"2026-05-23T11:09:02","modified_gmt":"2026-05-23T11:09:02","slug":"unnehe0003-2026-biopharma-immune-thrombocytopenic-purpura-unmet-need-unmet-need-immune-thrombocytopenic-purpura-us-eu","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unnehe0003-2026-biopharma-immune-thrombocytopenic-purpura-unmet-need-unmet-need-immune-thrombocytopenic-purpura-us-eu\/","title":{"rendered":"Immune Thrombocytopenic Purpura &#8211; Unmet Need &#8211; Unmet Need &#8211; Immune Thrombocytopenic Purpura (US\/EU)"},"content":{"rendered":"<p>Immune thrombocytopenic purpura (<abbr title=\"immune thrombocytopenic purpura\">ITP<\/abbr>) is an autoimmune disorder marked by increased platelet destruction and impaired megakaryocyte production. Bleeding ranges from petechiae to lifethreatening hemorrhage, and severity does not always match platelet count. The <abbr title=\"immune thrombocytopenic purpura\">ITP<\/abbr> treatment landscape is evolving as clinicians continue shifting away from chronic steroid use toward targeted, bettertolerated therapies. <abbr title=\"thrombopoietin\">TPO<\/abbr>receptor agonists such as Nplate (Amgen), Promacta \/ Revolade (Novartis), and Doptelet (Sobi) are foundational; however, competition is intensifying as drugs with diverse mechanisms such as the SKY inhibitor Tavalisse \/ Tavlesse (Rigel \/ Grifols) and the <abbr title=\"Bruton\u2019s tyrosine kinase\">BTK<\/abbr> inhibitor Wayrilz (Sanofi) become available.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>How important are clinical treatment attributes in hematologists\u2019 prescribing decisions?<\/li>\n<li>How do key current therapies, such as Nplate, Promacta \/ Revolade, and Doptelet, perform on key clinical drug attributes for <abbr title=\"immune thrombocytopenic purpura\">ITP<\/abbr>? How satisfied are hematologists with current therapies?<\/li>\n<li>What are the greatest unmet needs and most attractive opportunities in this patient population?<\/li>\n<li>What trade-offs are surveyed hematologists willing to make across key drug attributes and price when considering a hypothetical target product profile?<\/li>\n<\/ul>\n<p><strong>Product description<\/strong><\/p>\n<p><a>Unmet Need offers insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities, enabling you to:<\/a><\/p>\n<ul class=\"round-bullets\">\n<li>Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians\u2019 weightings and analysis of stated vs. derived importance.<\/li>\n<li>Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers.<\/li>\n<\/ul>\n<p><b>Geography: <\/b>United States, France, Germany, United Kingdom<\/p>\n<p><strong>Primary research: <\/strong>Survey of 60 U.S. and 30 European hematologists<\/p>\n<p><strong>Key drugs covered: <\/strong>Nplate, Promacta \/ Revolade, Doptelet, Tavalisse, Wayrilz<\/p>\n<p><strong>Key analyses:\u00a0<\/strong>Importance of clinical and nonclinical product attributes to physicians; assessment of current drug performance against treatment drivers and goals;\u00a0physician perceptions of unmet needs in the indication and related indications;\u00a0remaining drug development opportunities.<\/p>\n<p><strong>Key feature: <\/strong>Target Product Profile (<abbr data-abbreviation-entity=\"6194\" title=\"Target Product Profile\">TPP<\/abbr>) simulator tool allows for customizable market simulations based on conjoint analysis. Compare up to seven TPPs across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.<\/p>\n","protected":false},"template":"","class_list":["post-583002","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-hematology","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-2609"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/583002","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/583002\/revisions"}],"predecessor-version":[{"id":583034,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/583002\/revisions\/583034"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=583002"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}